{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:46:13Z","timestamp":1779003973289,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s13555-024-01123-1","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:01:26Z","timestamp":1710471686000},"page":"745-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03090100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02207231","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3440","authenticated-orcid":false,"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-5001","authenticated-orcid":false,"given":"Patricia","family":"Gorecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-9310","authenticated-orcid":false,"given":"Sven","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-380X","authenticated-orcid":false,"given":"Jozefien","family":"Buyze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2654-9459","authenticated-orcid":false,"given":"Lorenzo","family":"Acciarri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"6","key":"1123_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1123_CR2","doi-asserted-by":"publisher","first-page":"T33","DOI":"10.1016\/j.ad.2022.07.025","volume":"114","author":"K Nabieva","year":"2023","unstructured":"Nabieva K, Vender R. Quality of life and body region affected by psoriasis: a systematic review. Actas Dermosifiliogr. 2023;114(1):T33\u20138. https:\/\/doi.org\/10.1016\/j.ad.2022.07.025.","journal-title":"Actas Dermosifiliogr"},{"issue":"7","key":"1123_CR3","doi-asserted-by":"publisher","first-page":"Cd011535","DOI":"10.1002\/14651858.CD011535.pub6","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):Cd011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1123_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425\u201342. https:\/\/doi.org\/10.1007\/s40257-021-00603-w.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1123_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241604","volume":"15","author":"A Karpinska-Mirecka","year":"2020","unstructured":"Karpinska-Mirecka A, Bartosinska J, Krasowska D. The effects of selected biologics and a small molecule on health-related quality of life in adult plaque psoriasis patients: a systematic review and meta-analysis. PLoS ONE. 2020;15(12):e0241604. https:\/\/doi.org\/10.1371\/journal.pone.0241604.","journal-title":"PLoS ONE"},{"key":"1123_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","volume":"12","author":"CC de Ruiter","year":"2022","unstructured":"de Ruiter CC, Rustemeyer T. Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: a systematic review. Psoriasis (Auckl). 2022;12:99\u2013112. https:\/\/doi.org\/10.2147\/PTT.S356568.","journal-title":"Psoriasis (Auckl)"},{"issue":"10","key":"1123_CR7","doi-asserted-by":"publisher","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","volume":"101","author":"CW Schwarz","year":"2021","unstructured":"Schwarz CW, Loft N, Rasmussen MK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021;101(10):adv00579. https:\/\/doi.org\/10.2340\/actadv.v101.351.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1123_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","volume":"180","author":"RB Warren","year":"2019","unstructured":"Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069\u201376. https:\/\/doi.org\/10.1111\/bjd.16776.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1123_CR9","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340. https:\/\/doi.org\/10.1038\/jid.2015.208.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1123_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/09546634.2013.800184","volume":"25","author":"V Di Lernia","year":"2014","unstructured":"Di Lernia V, Ricci C, Lallas A, Ficarelli E. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat. 2014;25(1):73\u20134. https:\/\/doi.org\/10.3109\/09546634.2013.800184.","journal-title":"J Dermatolog Treat"},{"key":"1123_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/ptt.s328460","volume":"12","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M. Towards personalized medicine in psoriasis: current progress. Psoriasis (Auckl). 2022;12:231\u201350. https:\/\/doi.org\/10.2147\/ptt.s328460.","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"1123_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase\u00a0III, double-blinded, placebo- and active comparator-controlled VOYAGE\u00a01 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"1123_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/s0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase\u00a03, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"2","key":"1123_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/09546634.2020.1782817","volume":"33","author":"CEM Griffiths","year":"2022","unstructured":"Griffiths CEM, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4\u00a0years in patients with moderate-to-severe psoriasis: results from VOYAGE\u00a01. J Dermatolog Treat. 2022;33(2):848\u201356. https:\/\/doi.org\/10.1080\/09546634.2020.1782817.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1123_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/13543784.2023.2219387","volume":"32","author":"E Camela","year":"2023","unstructured":"Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537\u201352. https:\/\/doi.org\/10.1080\/13543784.2023.2219387.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1123_CR16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366. https:\/\/doi.org\/10.1111\/bjd.18333.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1123_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jamadermatol.2022.3171","volume":"158","author":"ML Nielsen","year":"2022","unstructured":"Nielsen ML, Petersen TC, Maul JT, et al. Multivariable predictive models to identify the optimal biologic therapy for treatment of patients with psoriasis at the individual level. JAMA Dermatol. 2022;158(10):1149\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3171.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1123_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000265557","volume":"220","author":"S Gerdes","year":"2010","unstructured":"Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology. 2010;220(1):38\u201343. https:\/\/doi.org\/10.1159\/000265557.","journal-title":"Dermatology"},{"issue":"5","key":"1123_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/aje\/kwr325","volume":"175","author":"W Li","year":"2012","unstructured":"Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175(5):402\u201313. https:\/\/doi.org\/10.1093\/aje\/kwr325.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1123_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/1744666x.2019.1543591","volume":"15","author":"E Pezzolo","year":"2019","unstructured":"Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2019;15(1):41\u20138. https:\/\/doi.org\/10.1080\/1744666x.2019.1543591.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"1123_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0300060520964024","volume":"48","author":"H Zhou","year":"2020","unstructured":"Zhou H, Wu R, Kong Y, Zhao M, Su Y. Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis. J Int Med Res. 2020;48(11):1\u201320. https:\/\/doi.org\/10.1177\/0300060520964024.","journal-title":"J Int Med Res"},{"issue":"8","key":"1123_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","volume":"31","author":"A Pinter","year":"2020","unstructured":"Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):769\u201375. https:\/\/doi.org\/10.1080\/09546634.2019.1626973.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1123_CR23","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Schakel","year":"2023","unstructured":"Schakel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): week\u00a028 results from the ongoing phase\u00a0IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327. https:\/\/doi.org\/10.1111\/jdv.19236.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1123_CR24","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/jcm9072170","volume":"9","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1\u00a0year real-life study. J Clin Med. 2020;9(7):2170. https:\/\/doi.org\/10.3390\/jcm9072170.","journal-title":"J Clin Med"},{"key":"1123_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406223211046685","volume":"12","author":"YT Hung","year":"2021","unstructured":"Hung YT, Lin YJ, Chiu HY, Huang YH. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice. Ther Adv Chronic Dis. 2021;12:1\u201312. https:\/\/doi.org\/10.1177\/20406223211046685.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"1123_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14712598.2014.900541","volume":"14","author":"N Al-Mutairi","year":"2014","unstructured":"Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14(6):749\u201356. https:\/\/doi.org\/10.1517\/14712598.2014.900541.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"1123_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","volume":"149","author":"P Jensen","year":"2013","unstructured":"Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149(7):795\u2013801. https:\/\/doi.org\/10.1001\/jamadermatol.2013.722.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1123_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/09546634.2015.1088130","volume":"27","author":"I Garcia-Doval","year":"2016","unstructured":"Garcia-Doval I, Perez-Zafrilla B, Ferrandiz C, et al. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat. 2016;27(3):203\u20139. https:\/\/doi.org\/10.3109\/09546634.2015.1088130.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1123_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jdermsci.2014.09.003","volume":"76","author":"JH Hoffmann","year":"2014","unstructured":"Hoffmann JH, Knoop C, Enk AH, Hadaschik EN. Baseline anti-dsDNA concentrations and previous treatments predict response to adalimumab and etanercept: a retrospective investigation of 146 psoriasis patients. J Dermatol Sci. 2014;76(3):180\u20135. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.09.003.","journal-title":"J Dermatol Sci"},{"issue":"8","key":"1123_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/1346-8138.12538","volume":"41","author":"Y Umezawa","year":"2014","unstructured":"Umezawa Y, Saeki H, Nakagawa H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol. 2014;41(8):690\u20136. https:\/\/doi.org\/10.1111\/1346-8138.12538.","journal-title":"J Dermatol"},{"issue":"3","key":"1123_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jdv.17829","volume":"36","author":"I van Ee","year":"2022","unstructured":"van Ee I, Deprez E, Egeberg A, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022;36(3):403\u201312. https:\/\/doi.org\/10.1111\/jdv.17829.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01123-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01123-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01123-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T16:27:01Z","timestamp":1711470421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01123-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01123-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexander Egeberg has received research funding from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, the Danish National Psoriasis Foundation, Eli Lilly, Janssen Pharmaceuticals, the Kgl Hofbundtmager Aage Bang Foundation, Novartis, Pfizer, and the Simon Spies Foundation, and honoraria as consultant or speaker from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galapagos NV, Galderma, Horizon Therapeutics, Janssen, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co., Ltd., Sun Pharmaceuticals, UCB, Union Therapeutics, and Zuellig Pharma Ltd. Since the completion of this work, Alexander Egeberg has changed affiliation. His new affiliation is LEO Pharma A\/S, Industriparken 55, DK-2750 Ballerup, Denmark. Curdin Conrad received research grants or served as a scientific adviser or clinical study investigator for AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, and UCB. Jozefien Buyze, Patricia Gorecki, and Sven Wegner are employees of Janssen; Sven Wegner holds stocks in Johnson & Johnson; Lorenzo Acciarri is an employee of Valos Srl, a Johnson & Johnson partner company. Diamant Tha\u00e7i has been a consultant, investigator, and speaker and participated in advisory boards for AbbVie, Almirall, Amgen, Biogen Idec, Bristol Myers Squibb, Janssen-Cilag, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and UCB, and has received research\/educational grants from AbbVie, LEO Pharma, Novartis, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The ECLIPSE and VOYAGE\u00a01 trials were sponsored by Janssen and conducted in accordance with the ethical principles derived from international guidelines, including the Declaration of Helsinki. An institutional review board or ethics committee approved the study protocol at participating sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}